Back to search

Peptide record

TPDB11145

kalata B1 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity standard
29 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11145
kalata B1
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP DRAMP Peptipedia Antifungipept CAFPdb AI4AVP dbAMP 3.0 DRAVP 2.0 CPPsite3.0 APD_complete APD_hemolytic HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 29-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
GLPVCGETCVGGTCNTPGCTCSWPVCTRN
Physicochemical Analysis
C117H187N35O40S6
ADQHIKMFY
C
2916.34
5.90
1
1
5
-0
2.26
0.152
43.45
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
5875
201.45
14
Residue Composition
number
0
A
1
R
2
N
0
D
6
C
1
E
0
Q
5
G
0
H
0
I
1
L
0
K
0
M
0
F
3
P
1
S
5
T
1
W
0
Y
3
V
Amino Acid Distribution
A: 0 R: 1 N: 2 D: 0 C: 6 E: 1 Q: 0 G: 5 H: 0 I: 0 L: 1 K: 0 M: 0 F: 0 P: 3 S: 1 T: 5 W: 1 Y: 0 V: 3
Chemical Descriptors
29
C117H187N35O40S6
2916.34
5.90
-0
2.26
0.152
Free
L
Hydrophobic and amphiphilic
Cyclic
Free
NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(=O)N)C(=O)O
Evidence Records 40 records
Evidence 1 Activity

Activity

MIC
Antibacterial
>500 µM

Target

E.coli

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against Gram- E.coli (MIC >500 uM), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S.
Evidence 2 Activity

Activity

MIC
Antibacterial
>500 µM

Target

P.vulgaris

Source & Reference

dbAMP DRAMP

Other

Active against Gram- E.coli (MIC >500 uM), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi
Evidence 3 Activity

Activity

MIC
Antibacterial
54.8 µM

Target

Klebsiella oxytoca

Source & Reference

dbAMP DRAMP

Other

against Gram- E.coli (MIC >500 uM), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM),
Evidence 4 Activity

Activity

MIC
Antibacterial
0.26 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP

Other

M), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.
Evidence 5 Activity

Activity

MIC
Antibacterial
40.4 µM

Target

M. luteus

Source & Reference

dbAMP DRAMP

Other

0 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.tropicalis (MIC >500 uM)
Evidence 6 Activity

Activity

MIC
Antibacterial
21.4 µM

Target

C. kefyr

Source & Reference

dbAMP DRAMP

Other

Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.tropicalis (MIC >500 uM) (see ref). Also, it inhibited HIV-1 infection in cultured
Evidence 7 Activity

Activity

MIC
Antibacterial
>500 µM

Target

C.tropicalis

Source & Reference

dbAMP DRAMP

Other

M), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.tropicalis (MIC >500 uM) (see ref). Also, it inhibited HIV-1 infection in cultured human T-lymphoblast (CEM-SS) ce
Evidence 8 Activity

Activity

MIC
Antifungal
>500 µM

Target

E.coli

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against Gram- E.coli (MIC >500 uM), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S.
Evidence 9 Activity

Activity

MIC
Antifungal
>500 µM

Target

P.vulgaris

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against Gram- E.coli (MIC >500 uM), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi
Evidence 10 Activity

Activity

MIC
Antifungal
54.8 µM

Target

Klebsiella oxytoca

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

against Gram- E.coli (MIC >500 uM), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM),
Evidence 11 Activity

Activity

MIC
Antifungal
0.26 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

M), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.
Evidence 12 Activity

Activity

MIC
Antifungal
40.4 µM

Target

M. luteus

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

0 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.tropicalis (MIC >500 uM)
Evidence 13 Activity

Activity

MIC
Antifungal
21.4 µM

Target

C. kefyr

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.tropicalis (MIC >500 uM) (see ref). Also, it inhibited HIV-1 infection in cultured
Evidence 14 Activity

Activity

MIC
Antifungal
>500 µM

Target

C.tropicalis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

M), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.tropicalis (MIC >500 uM) (see ref). Also, it inhibited HIV-1 infection in cultured human T-lymphoblast (CEM-SS) ce
Evidence 15 Activity

Activity

MIC
Antiparasitic
>500 µM

Target

E.coli

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
Active against Gram- E.coli (MIC >500 uM), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S.
Evidence 16 Activity

Activity

MIC
Antiparasitic
>500 µM

Target

P.vulgaris

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against Gram- E.coli (MIC >500 uM), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi
Evidence 17 Activity

Activity

MIC
Antiparasitic
54.8 µM

Target

Klebsiella oxytoca

Source & Reference

dbAMP 3.0 DRAMP

Other

against Gram- E.coli (MIC >500 uM), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM),
Evidence 18 Activity

Activity

MIC
Antiparasitic
0.26 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP 3.0 DRAMP

Other

M), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.
Evidence 19 Activity

Activity

MIC
Antiparasitic
40.4 µM

Target

M. luteus

Source & Reference

dbAMP 3.0 DRAMP

Other

0 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.tropicalis (MIC >500 uM)
Evidence 20 Activity

Activity

MIC
Antiparasitic
21.4 µM

Target

C. kefyr

Source & Reference

dbAMP 3.0 DRAMP

Other

Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.tropicalis (MIC >500 uM) (see ref). Also, it inhibited HIV-1 infection in cultured
Evidence 21 Activity

Activity

MIC
Antiparasitic
>500 µM

Target

C.tropicalis

Source & Reference

dbAMP 3.0 DRAMP

Other

M), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.tropicalis (MIC >500 uM) (see ref). Also, it inhibited HIV-1 infection in cultured human T-lymphoblast (CEM-SS) ce
Evidence 22 Activity

Activity

MIC
Antiviral
>500 µM

Target

E.coli

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
Active against Gram- E.coli (MIC >500 uM), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S.
Evidence 23 Activity

Activity

MIC
Antiviral
>500 µM

Target

P.vulgaris

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Active against Gram- E.coli (MIC >500 uM), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi
Evidence 24 Activity

Activity

MIC
Antiviral
54.8 µM

Target

Klebsiella oxytoca

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

against Gram- E.coli (MIC >500 uM), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM),
Evidence 25 Activity

Activity

MIC
Antiviral
0.26 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

M), P.aeruginosa (MIC> 500 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.
Evidence 26 Activity

Activity

MIC
Antiviral
40.4 µM

Target

M. luteus

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

0 uM), P.vulgaris (MIC >500 uM), K. oxytoca (MIC 54.8 uM), Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.tropicalis (MIC >500 uM)
Evidence 27 Activity

Activity

MIC
Antiviral
21.4 µM

Target

C. kefyr

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Gram+ S. aureus (MIC 0.26 uM), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.tropicalis (MIC >500 uM) (see ref). Also, it inhibited HIV-1 infection in cultured
Evidence 28 Activity

Activity

MIC
Antiviral
>500 µM

Target

C.tropicalis

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

M), M. luteus (MIC 40.4 uM), fungi C.albicans (MIC > 500 uM), C. kefyr (MIC 21.4 uM), and C.tropicalis (MIC >500 uM) (see ref). Also, it inhibited HIV-1 infection in cultured human T-lymphoblast (CEM-SS) ce
Evidence 29 Activity

Activity

Cell-penetrating Peptides

Target

Cd34+ Endothelial Cells , HNSCS, Neurons And Astrocytes

Assay & Model

Male Sprague Dawley rats weighing 250–300 g
Male Sprague Dawley rats weighing 250–300 g

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Cyclic L Hydrophobic and amphiphilic
Protein derived
Kp,uu,brain, of 0.5% of unbound kalata B1 equilibrated across the BBB in rat. model.
Endocytosis
In vitro and in vivo
CCCCCSCSTTTTTSCCSSSSCSCSSCTTC
Evidence 30 Activity

Activity

HD50
Hemolysis
300 µM
[Ref.12779323] HD50 = 300 µM against Human type A red blood cells.

Target

Human type A red blood cells

Source & Reference

Hemolytik APD_complete APD_hemolytic PD_Hemolysis
DRAMP4
Biopolymers. 2008 90(1):51-60.##Proc Natl Acad Sci U S A. 1999 Aug 3 96(16):8913-8918.##Biochemistry. 1995 Apr 4 34(13):4147-4158.##Chembiochem. 2007 Jun 18 8(9):1001-1011.##J Biol Chem. 2012 Dec 21 287(52):43884-98.

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation. Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 31 Activity

Activity

50% Hemolysis
Toxicity
26 µM
Hemolytic Cytotoxic
50% Hemolysis | 26 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A Synthetic mirror image of kalata B1 reveals that cyclotide activity is independent of a protein receptor. | Chembiochem | 2011
Evidence 32 Activity

Activity

IC50
Toxicity
2.38±0.09 µM
Cytotoxic
IC50 | 2.38±0.09 | µM | target cell: Human foreskin fibroblasts (HFF)

Target

Human foreskin fibroblasts (HFF)

Source & Reference

NA
DBAASP
Isolation and characterization of cytotoxic cyclotides from Viola philippica. | Peptides | 2011
Evidence 33 Activity

Activity

41% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
41% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Decoding the membrane activity of the cyclotide kalata B1: the importance of phosphatidylethanolamine phospholipids and lipid organization on hemolytic and anti-HIV activities. | J Biol Chem | 2011
Evidence 34 Activity

Activity

IC50
Toxicity
5.7 µM
Cytotoxic
IC50 | 5.7 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Anti-HIV cyclotides from the Chinese medicinal herb Viola yedoensis | J Nat Prod | 2008
Evidence 35 Activity

Activity

50% Hemolysis
Toxicity
29.1±1.1 µM
Hemolytic Cytotoxic
50% Hemolysis | 29.1±1.1 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Anticancer and toxic properties of cyclotides are dependent on phosphatidylethanolamine phospholipid targeting | Chembiochem | 2014
Evidence 36 Activity

Activity

50% Cell death
Toxicity
11.2±0.5 µM
Cytotoxic
50% Cell death | 11.2±0.5 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Anticancer and toxic properties of cyclotides are dependent on phosphatidylethanolamine phospholipid targeting | Chembiochem | 2014
Evidence 37 Activity

Activity

50% Cell death
Toxicity
12.0±0.5 µM
Cytotoxic
50% Cell death | 12.0±0.5 | µM | target cell: Human foreskin fibroblasts (HFF)

Target

Human foreskin fibroblasts (HFF)

Source & Reference

NA
DBAASP
Anticancer and toxic properties of cyclotides are dependent on phosphatidylethanolamine phospholipid targeting | Chembiochem | 2014
Evidence 38 Activity

Activity

3% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
3% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Decoding the membrane activity of the cyclotide kalata B1: the importance of phosphatidylethanolamine phospholipids and lipid organization on hemolytic and anti-HIV activities. | J Biol Chem | 2011
Evidence 39 Activity

Activity

HD50
Toxicity
300 µM
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.12779323] HD50 = 300 µM against Human type A red blood cells. | Cytotoxicity: [Ref.18008336]CEM-SS cells:IC50=3500 nM.

Target

erythrocytes

Source & Reference

NA
DRAMP
Biopolymers. 2008 90(1):51-60.##Proc Natl Acad Sci U S A. 1999 Aug 3 96(16):8913-8918.##Biochemistry. 1995 Apr 4 34(13):4147-4158.##Chembiochem. 2007 Jun 18 8(9):1001-1011.##J Biol Chem. 2012 Dec 21 287(52):43884-98.
Evidence 40 Hemolysis

Activity

300 µM
HD50
[Ref.12779323] HD50 = 300 µM against Human type A red blood cells.
Hemolysis

Target

Human type A red blood cells

Source & Reference

APD_complete APD_hemolytic HemoPI PD_Hemolysis
Biopolymers. 2008 90(1):51-60.##Proc Natl Acad Sci U S A. 1999 Aug 3 96(16):8913-8918.##Biochemistry. 1995 Apr 4 34(13):4147-4158.##Chembiochem. 2007 Jun 18 8(9):1001-1011.##J Biol Chem. 2012 Dec 21 287(52):43884-98.
DRAMP4
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.
Additional Detail Fields 1 fields
CCCCCSCSTTTTTSCCSSSSCSCSSCTTC